Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 50-14 OLYMPIA 

A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

DESIGN

please click on the picture to see a larger version

Study Chair
Dr. Lorenzo Gianni, Rimini, Italy

Lead Trial Coordinator
Holly Shaw

Trial Coordinators
Poonam Jani

Trial Monitor
Giuseppe Achille, Daniela Celotto, Carmen Comune

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: OLYMPIA-monitoring@ibcsg.org

Date of Activation
July 25, 2014

Targeted Accrual
1320


News

23.03.2019:
The next IBCSG Annual Meeting will take place in Vienna Austria on March 23 and 24, 2019.       

17.09.2018:
New publications are available 

17.09.2018:
Clinical Trials

All News

 
  Print